Key result
Nurr1 haplotypes linked to in-stent restenosis risk, with Nurr1 limiting vascular smooth muscle proliferation.
Cohort (n=601)
Prospective cohort study shows Nurr1 haplotypes and expression regulate vascular lesion formation in stented patients and mice, indicating a therapeutic target for restenosis.
BACKGROUND: Restenosis is the major drawback of percutaneous coronary interventions involving excessive activation and proliferation of vascular smooth muscle cells (SMCs). The nuclear receptor Nurr1 is an early response gene known mainly for its critical role in the development of dopamine neurons. In the present study, we investigated Nurr1 in human and experimental vascular restenosis. METHODS AND RESULTS: In a prospective cohort of 601 patients undergoing percutaneous coronary intervention, including stent placement, we found a strong association between Nurr1 haplotypes and in-stent restenosis risk. Furthermore, Nurr1 is specifically expressed in human in-stent restenosis and induced in cultured human SMCs in response to serum or tumor necrosis factor-alpha. Lentivirus-mediated gain- and loss-of-function experiments in SMCs demonstrated that overexpression of Nurr1 inhibited proliferation, consistent with increased expression of the key cell-cycle inhibitor p27(Kip1), whereas Nurr1 silencing enhanced SMC growth. The tumor necrosis factor-alpha-induced proinflammatory response of SMCs is inhibited by Nurr1, as reflected by reduced interleukin-1beta, tumor necrosis factor-alpha, and monocyte chemoattractant protein-1 expression. Consistent with our in vitro data, endogenous Nurr1 reduced wire injury-induced proliferation and vascular lesion formation in carotid arteries of ApoE(-/-) mice. CONCLUSIONS: Nurr1 haplotypes are associated with human restenosis risk, and Nurr1 is expressed in human in-stent restenosis. In SMCs, Nurr1 inhibits proliferation and inflammatory responses, which explains the inhibition of SMC-rich lesion formation in mice. The recently identified small-molecule drugs that enhance the activity of Nurr1 reveal this nuclear receptor as an attractive novel target for (local) intervention in restenosis.
No takes yet. Share an insight, caveat, or question.
Bonta et al. (2010) conducted a cohort in In-stent restenosis (n=601). Nurr1 haplotypes / expression was evaluated on In-stent restenosis risk. Nurr1 haplotypes were strongly associated with in-stent restenosis risk in 601 PCI patients, and Nurr1 inhibited smooth muscle cell proliferation and lesion formation in mice.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: